physician registration for schedule i drugs

Summary#

This bill creates a special federal registration for doctors to directly give certain Schedule I investigational drugs to patients under the Federal Right to Try law. The main change is a new process that lets physicians apply to the Attorney General (through the Drug Enforcement Administration) for permission to possess and administer those drugs to eligible patients. The stated policy goal is to allow eligible patients quicker access to investigational Schedule I drugs while setting conditions to reduce diversion (illegal distribution).

• Main change: adds a new registration pathway for physicians to treat eligible patients with Schedule I investigational drugs covered by the Federal Right to Try law.
• Application rules: doctors must submit proof they are already registered to handle other controlled substances, show manufacturer/sponsor documentation and agreement to supply the drug, confirm state law allows the treatment, describe training and site security, and list quantities requested.
• Timing: the Attorney General must approve or begin a show-cause process within 45 days of a complete application. Supplemental requests for more drug quantities are deemed approved after 30 days unless a show-cause order is issued.
• Site rules: one registration can cover multiple treatment sites if they are in the same city or county and under the same institution, with notice to the Attorney General.
• Rulemaking: the Attorney General must issue an interim final rule to implement the process within 240 days (skipping the usual notice-and-comment step at that stage) and a final rule within two years.

What it means for you#

• Physicians

  • A new federal registration lets approved doctors possess and directly give certain Schedule I investigational drugs to eligible Right to Try patients.
  • Doctors must provide documentation of training, state law compliance, storage site, and a manufacturer’s agreement to supply the drug.
  • Doctors’ possession of the drug is limited to the amounts listed in the application or in a supplemental notice.

• Patients (eligible under Right to Try)

  • This could make it easier for eligible, seriously ill patients to receive certain Schedule I investigational drugs from registered physicians.
  • The bill ties access to compliance with the Federal Right to Try eligibility rules (as defined in the referenced law).

• Drug manufacturers or sponsors

  • Manufacturers must provide documentation that a drug is eligible and must agree to supply the drug and provide administration guidance to the treating physician.

• Hospitals, clinics, and treatment sites

  • A single physician registration may cover multiple sites if they are in the same city or county and under the same institution, but each site must be notified to the Attorney General beforehand.
  • Sites must meet storage and security requirements that the Attorney General will define.

• Federal agencies (Attorney General / DEA)

  • The Attorney General must set up a new registration system, accept electronic applications, process applications within 45 days, and write interim and final rules.

• States

  • Physicians must show they may lawfully provide the treatment under state law. The bill does not change state authority; it requires evidence of state-law compliance.

Expenses#

No publicly available information.

• The bill requires new federal rulemaking and a registration process. This would likely increase administrative work for the Department of Justice / DEA (rule writing, application processing, record-keeping, inspections), but the bill does not include a cost estimate.
• Physicians, hospitals, and manufacturers may face compliance costs (preparing documentation, meeting security and record-keeping rules, training).
• No new fees or specific funding are set in the bill text.

Proponents' View#

• The bill appears intended to create a clear federal path for doctors to give eligible Schedule I investigational drugs to patients covered by the Federal Right to Try law.
• It could be seen as speeding patient access by setting firm response deadlines for federal approval (45 days for applications; 30 days for supplemental amounts).
• The application requirements (manufacturer agreement, training, storage description) could be seen as building safeguards against diversion and misuse.
• Allowing a single registration for related sites could reduce paperwork for physicians who treat patients at multiple locations under the same institution.

Opponents' View#

• One concern is that the bill requires an interim final rule without the usual public notice-and-comment process, which reduces early public input on safety and implementation details.
• The bill does not fully specify how diversion (illegal distribution) will be prevented in practice; key operational details are left to the Attorney General’s rules.
• It is unclear how much additional staff and money the DEA/Department of Justice will need to process applications, supervise registrants, and enforce controls.
• The bill relies on documentation of state-law compliance but does not explain how conflicts between federal permission and state restrictions would be handled.
• The bill does not detail required reporting of patient outcomes, adverse events, or monitoring rules beyond what is referenced in the Right to Try statute, leaving questions about patient safety oversight.